{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:48Z","timestamp":1793414148890,"version":"4.5.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hemophilia B is a blood clotting disorder caused by deficient activity of coagulation factor IX (FIX). Multiple recombinant FIX proteins are currently approved to treat hemophilia B, and several gene therapy products are currently being developed. Codon optimization is a frequently used technique in the pharmaceutical industry to improve recombinant protein expression by recoding a coding sequence using multiple synonymous codon substitutions. The underlying assumption of this gene recoding is that synonymous substitutions do not alter protein characteristics because the primary sequence of the protein remains unchanged. However, a critical body of evidence shows that synonymous variants can affect cotranslational folding and protein function. Gene recoding could potentially alter the structure, function, and in\u00a0vivo immunogenicity of recoded therapeutic proteins. Here, we evaluated multiple recoded variants of F9 designed to further explore the effects of codon usage bias on protein properties. The detailed evaluation of these constructs showed altered conformations, and assessment of translation kinetics by ribosome profiling revealed differences in local translation kinetics. Assessment of wild-type and recoded constructs using a major histocompatibility complex (MHC)-associated peptide proteomics assay showed distinct presentation of FIX-derived peptides bound to MHC class II molecules, suggesting that despite identical amino acid sequence, recoded proteins could exhibit different immunogenicity risks. Posttranslational modification analysis indicated that overexpression from gene recoding results in suboptimal posttranslational processing. Overall, our results highlight potential functional and immunogenicity concerns associated with gene-recoded F9 products. These findings have general applicability and implications for other gene-recoded recombinant proteins.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007094","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T19:36:39Z","timestamp":1649792199000},"page":"3932-3944","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Structural, functional, and immunogenicity implications of <i>F9<\/i> gene recoding"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8145-8894","authenticated-orcid":false,"given":"Upendra K.","family":"Katneni","sequence":"first","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Alexaki","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Hunt","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-9435","authenticated-orcid":false,"given":"Nobuko","family":"Hamasaki-Katagiri","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaya K.","family":"Hettiarachchi","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Kames","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-3822","authenticated-orcid":false,"given":"Joseph R.","family":"McGill","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Holcomb","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Athey","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-8908","authenticated-orcid":false,"given":"Leonid A.","family":"Parunov","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Kafri","sequence":"additional","affiliation":[{"name":"2Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lu","sequence":"additional","affiliation":[{"name":"3Bioverativ, Waltham; MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Peters","sequence":"additional","affiliation":[{"name":"3Bioverativ, Waltham; MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail V.","family":"Ovanesov","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-5174","authenticated-orcid":false,"given":"Dar\u00f3n I.","family":"Freedberg","sequence":"additional","affiliation":[{"name":"4Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Bar","sequence":"additional","affiliation":[{"name":"5Department of Statistics, University of Connecticut, Storrs, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-0633","authenticated-orcid":false,"given":"Anton A.","family":"Komar","sequence":"additional","affiliation":[{"name":"6Center for Gene Regulation in Health and Disease, Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuben E.","family":"Sauna","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-8585","authenticated-orcid":false,"given":"Chava","family":"Kimchi-Sarfaty","sequence":"additional","affiliation":[{"name":"1Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2022070615215683100_B1","first-page":"1","volume-title":"New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins.","author":"Pohlscheidt","year":"2018"},{"key":"2022070615215683100_B2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagass\u00e9","year":"2017","journal-title":"F1000 Res."},{"key":"2022070615215683100_B3","author":"US Food and Drug Administration"},{"issue":"1","key":"2022070615215683100_B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12859-017-1793-7","article-title":"A new and updated resource for codon usage tables","volume":"18","author":"Athey","year":"2017","journal-title":"BMC Bioinformatics."},{"key":"2022070615215683100_B5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fbioe.2014.00041","article-title":"Computational tools and algorithms for designing customized synthetic genes","volume":"2","author":"Gould","year":"2014","journal-title":"Front Bioeng Biotechnol."},{"issue":"41","key":"2022070615215683100_B6","doi-asserted-by":"crossref","first-page":"E6117","DOI":"10.1073\/pnas.1606724113","article-title":"Codon usage is an important determinant of gene expression levels largely through its effects on transcription","volume":"113","author":"Zhou","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2022070615215683100_B7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell."},{"issue":"4","key":"2022070615215683100_B8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2016.04.034","article-title":"Dynamics of translation of single mRNA molecules in\u00a0vivo","volume":"165","author":"Yan","year":"2016","journal-title":"Cell."},{"issue":"8","key":"2022070615215683100_B9","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1002\/mgg3.840","article-title":"Splicing dysregulation contributes to the pathogenicity of several F9 exonic point variants","volume":"7","author":"Katneni","year":"2019","journal-title":"Mol Genet Genomic Med."},{"issue":"37","key":"2022070615215683100_B10","doi-asserted-by":"crossref","first-page":"28741","DOI":"10.1074\/jbc.M110.154575","article-title":"A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein","volume":"285","author":"Bartoszewski","year":"2010","journal-title":"J Biol Chem."},{"issue":"22","key":"2022070615215683100_B11","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.3390\/ijms20225734","article-title":"A single synonymous variant (c.354G&gt;A [p.P118P]) in ADAMTS13 confers enhanced specific activity","volume":"20","author":"Hunt","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"5811","key":"2022070615215683100_B12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science."},{"issue":"11","key":"2022070615215683100_B13","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1096\/fj.13-227330","article-title":"The silent codon change I507-ATC-&gt;ATT contributes to the severity of the \u0394F508 CFTR channel dysfunction","volume":"27","author":"Lazrak","year":"2013","journal-title":"FASEB J."},{"issue":"5","key":"2022070615215683100_B14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jmedgenet-2016-104072","article-title":"Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B","volume":"54","author":"Simhadri","year":"2017","journal-title":"J Med Genet."},{"key":"2022070615215683100_B15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-biochem-071320-112701","article-title":"Synonymous but not silent: the codon usage code for gene expression and protein folding","volume":"90","author":"Liu","year":"2021","journal-title":"Annu Rev Biochem."},{"issue":"3","key":"2022070615215683100_B16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molcel.2016.01.008","article-title":"Synonymous codons direct cotranslational folding toward different protein conformations","volume":"61","author":"Buhr","year":"2016","journal-title":"Mol Cell."},{"issue":"3","key":"2022070615215683100_B17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0014-5793(99)01566-5","article-title":"Synonymous codon substitutions affect ribosome traffic and protein folding during in\u00a0vitro translation","volume":"462","author":"Komar","year":"1999","journal-title":"FEBS Lett."},{"issue":"7","key":"2022070615215683100_B18","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1907126117","article-title":"Synonymous codon substitutions perturb cotranslational protein folding in\u00a0vivo and impair cell fitness","volume":"117","author":"Walsh","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"issue":"14","key":"2022070615215683100_B19","doi-asserted-by":"crossref","first-page":"8484","DOI":"10.1093\/nar\/gkx501","article-title":"Codon usage regulates protein structure and function by affecting translation elongation speed in Drosophila cells","volume":"45","author":"Zhao","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"2022070615215683100_B20","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1158\/0008-5472.CAN-07-2377","article-title":"Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer","volume":"67","author":"Sauna","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"2022070615215683100_B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/jmg.33.5.437","article-title":"Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at -22 bp from the 5\u2032 splice site causes skipping of exon 3","volume":"33","author":"Llewellyn","year":"1996","journal-title":"J Med Genet."},{"key":"2022070615215683100_B22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biocel.2015.03.011","article-title":"Decoding mechanisms by which silent codon changes influence protein biogenesis and function","volume":"64","author":"Bali","year":"2015","journal-title":"Int J Biochem Cell Biol."},{"issue":"7","key":"2022070615215683100_B23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tig.2014.04.006","article-title":"Exposing synonymous mutations","volume":"30","author":"Hunt","year":"2014","journal-title":"Trends Genet."},{"issue":"2","key":"2022070615215683100_B24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2006.03.007","article-title":"Neuronal tissue-specific ribonucleoprotein complex formation on SOD1 mRNA: alterations by ALS SOD1 mutations","volume":"23","author":"Ge","year":"2006","journal-title":"Neurobiol Dis."},{"issue":"3","key":"2022070615215683100_B25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","article-title":"Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor","volume":"12","author":"Duan","year":"2003","journal-title":"Hum Mol Genet."},{"issue":"1","key":"2022070615215683100_B26","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1038\/s41598-019-51984-2","article-title":"Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies","volume":"9","author":"Alexaki","year":"2019","journal-title":"Sci Rep."},{"issue":"7439","key":"2022070615215683100_B27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature11833","article-title":"Non-optimal codon usage affects expression, structure and function of clock protein FRQ","volume":"495","author":"Zhou","year":"2013","journal-title":"Nature."},{"key":"2022070615215683100_B28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.omtm.2017.01.002","article-title":"Codon optimization leads to functional impairment of RD114-TR envelope glycoprotein","volume":"4","author":"Zucchelli","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"10","key":"2022070615215683100_B29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","article-title":"Evaluating and mitigating the immunogenicity of therapeutic proteins","volume":"36","author":"Sauna","year":"2018","journal-title":"Trends Biotechnol."},{"key":"2022070615215683100_B30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol."},{"issue":"4","key":"2022070615215683100_B31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/bab.32","article-title":"Stable and high-level production of recombinant factor IX in human hepatic cell line","volume":"58","author":"de Castilho Fernandes","year":"2011","journal-title":"Biotechnol Appl Biochem."},{"issue":"5","key":"2022070615215683100_B32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/hae.12943","article-title":"Optimization of the thrombin generation test components to measure potency of factor VIII concentrates","volume":"22","author":"Jha","year":"2016","journal-title":"Haemophilia."},{"key":"2022070615215683100_B33","author":"Stuart","year":"2010","edition":"6th ed."},{"key":"2022070615215683100_B34","volume-title":".","author":"Elandt-Johnson","year":"2014"},{"issue":"1","key":"2022070615215683100_B35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor\u00a0VIII-Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost."},{"key":"2022070615215683100_B36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.12688\/f1000research.22400.1","article-title":"Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX","volume":"9","author":"Alexaki","year":"2020","journal-title":"F1000 Res."},{"issue":"9","key":"2022070615215683100_B37","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","article-title":"Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products","volume":"3","author":"Jankowski","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"2022070615215683100_B38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/nar\/15.3.1281","article-title":"The Codon Adaptation Index \u2013 a measure of directional synonymous codon usage bias, and its potential applications","volume":"15","author":"Sharp","year":"1987","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"2022070615215683100_B39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol Med."},{"issue":"1","key":"2022070615215683100_B40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/MCB.21.1.298-309.2001","article-title":"Position effects are influenced by the orientation of a transgene with respect to flanking chromatin","volume":"21","author":"Feng","year":"2001","journal-title":"Mol Cell Biol."},{"key":"2022070615215683100_B41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-60761-533-0_5","article-title":"Strategies to insulate lentiviral vector-expressed transgenes","volume":"614","author":"Ramezani","year":"2010","journal-title":"Methods Mol Biol."},{"issue":"10","key":"2022070615215683100_B42","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric Fc fusion protein","volume":"115","author":"Peters","year":"2010","journal-title":"Blood."},{"issue":"2","key":"2022070615215683100_B43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10930-014-9550-5","article-title":"Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin","volume":"33","author":"Liu","year":"2014","journal-title":"Protein J."},{"issue":"5924","key":"2022070615215683100_B44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1168978","article-title":"Genome-wide analysis in\u00a0vivo of translation with nucleotide resolution using ribosome profiling","volume":"324","author":"Ingolia","year":"2009","journal-title":"Science."},{"key":"2022070615215683100_B45","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fimmu.2020.00698","article-title":"Applying MAPPs assays to assess drug immunogenicity","volume":"11","author":"Karle","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"2022070615215683100_B46","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.molcel.2015.07.018","article-title":"Codon usage influences the local rate of translation elongation to regulate co-translational protein folding","volume":"59","author":"Yu","year":"2015","journal-title":"Mol Cell."},{"key":"2022070615215683100_B47","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14204","article-title":"In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications","author":"Canis","year":"2018","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022070615215683100_B48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.moh.0000239702.40297.ec","article-title":"Risk of inhibitors in haemophilia and the type of factor replacement","volume":"13","author":"Goudemand","year":"2006","journal-title":"Curr Opin Hematol."},{"issue":"6","key":"2022070615215683100_B49","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"24","key":"2022070615215683100_B50","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2016-11-750885","article-title":"Biological considerations of plasma-derived and recombinant factor VIII immunogenicity","volume":"129","author":"Lai","year":"2017","journal-title":"Blood."},{"issue":"21","key":"2022070615215683100_B51","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"issue":"11","key":"2022070615215683100_B52","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1021\/pr200503g","article-title":"Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells","volume":"10","author":"Bozzacco","year":"2011","journal-title":"J Proteome Res."},{"issue":"1","key":"2022070615215683100_B53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.jproteome.6b00386","article-title":"Immunogenic HLA-DR-presented self-peptides identified directly from clinical samples of synovial tissue, synovial fluid, or peripheral blood in patients with rheumatoid arthritis or lyme arthritis","volume":"16","author":"Wang","year":"2017","journal-title":"J Proteome Res."},{"key":"2022070615215683100_B54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fimmu.2015.00464","article-title":"Endogenous antigen presentation of MHC class II epitopes through non-autophagic pathways","volume":"6","author":"Leung","year":"2015","journal-title":"Front Immunol."},{"issue":"1","key":"2022070615215683100_B55","first-page":"51","article-title":"A highly productive CHO cell line secreting human blood clotting factor IX","volume":"10","author":"Kovnir","year":"2018","journal-title":"Acta Naturae."},{"key":"2022070615215683100_B56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-94-011-5404-8_79","volume-title":"Animal Cell Technology: From Vaccines to Genetic Medicine.","author":"Hamilton","year":"1997"},{"issue":"22","key":"2022070615215683100_B57","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2022070615215683100_B58","doi-asserted-by":"crossref","first-page":"e113600","DOI":"10.1371\/journal.pone.0113600","article-title":"A single chain variant of factor VIII Fc fusion protein retains normal in\u00a0vivo efficacy but exhibits altered in\u00a0vitro activity","volume":"9","author":"Buyue","year":"2014","journal-title":"PLoS One."},{"key":"2022070615215683100_B59","volume-title":"Human Gene Therapy for Hemophilia.","author":"US\u00a0Food and Drug Administration"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3932\/1905512\/advancesadv2022007094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3932\/1905512\/advancesadv2022007094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:22:53Z","timestamp":1657120973000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3932\/484886\/Structural-functional-and-immunogenicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":59,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007094","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}